JP2010520875A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010520875A5 JP2010520875A5 JP2009552762A JP2009552762A JP2010520875A5 JP 2010520875 A5 JP2010520875 A5 JP 2010520875A5 JP 2009552762 A JP2009552762 A JP 2009552762A JP 2009552762 A JP2009552762 A JP 2009552762A JP 2010520875 A5 JP2010520875 A5 JP 2010520875A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- oxo
- hydroxy
- dihydro
- ethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims description 97
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 37
- 125000000217 alkyl group Chemical group 0.000 claims description 34
- 125000001475 halogen functional group Chemical group 0.000 claims description 29
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 25
- 208000035475 disorder Diseases 0.000 claims description 21
- 208000004296 neuralgia Diseases 0.000 claims description 21
- 208000002193 Pain Diseases 0.000 claims description 20
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 18
- 201000010099 disease Diseases 0.000 claims description 16
- 230000001404 mediated effect Effects 0.000 claims description 15
- 125000003545 alkoxy group Chemical group 0.000 claims description 14
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 14
- -1 hydroxy, amino Chemical group 0.000 claims description 14
- 208000037765 diseases and disorders Diseases 0.000 claims description 12
- 208000003251 Pruritus Diseases 0.000 claims description 10
- 229910052739 hydrogen Inorganic materials 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 208000023504 respiratory system disease Diseases 0.000 claims description 9
- 125000003282 alkyl amino group Chemical group 0.000 claims description 8
- 239000001257 hydrogen Substances 0.000 claims description 8
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 8
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 8
- 208000023275 Autoimmune disease Diseases 0.000 claims description 7
- 206010020751 Hypersensitivity Diseases 0.000 claims description 7
- 208000021722 neuropathic pain Diseases 0.000 claims description 7
- 206010061218 Inflammation Diseases 0.000 claims description 6
- 208000019695 Migraine disease Diseases 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 208000018737 Parkinson disease Diseases 0.000 claims description 6
- 206010043269 Tension headache Diseases 0.000 claims description 6
- 208000008548 Tension-Type Headache Diseases 0.000 claims description 6
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 6
- 206010003246 arthritis Diseases 0.000 claims description 6
- 125000003118 aryl group Chemical group 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 6
- 206010015037 epilepsy Diseases 0.000 claims description 6
- 230000004054 inflammatory process Effects 0.000 claims description 6
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 6
- 206010027599 migraine Diseases 0.000 claims description 6
- 239000000651 prodrug Substances 0.000 claims description 6
- 229940002612 prodrug Drugs 0.000 claims description 6
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 239000012453 solvate Substances 0.000 claims description 6
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 6
- 208000004371 toothache Diseases 0.000 claims description 6
- 230000009529 traumatic brain injury Effects 0.000 claims description 6
- 208000019901 Anxiety disease Diseases 0.000 claims description 5
- 201000001320 Atherosclerosis Diseases 0.000 claims description 5
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims description 5
- 208000020925 Bipolar disease Diseases 0.000 claims description 5
- 206010069632 Bladder dysfunction Diseases 0.000 claims description 5
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 5
- 208000000094 Chronic Pain Diseases 0.000 claims description 5
- 208000006561 Cluster Headache Diseases 0.000 claims description 5
- 208000030814 Eating disease Diseases 0.000 claims description 5
- 208000034347 Faecal incontinence Diseases 0.000 claims description 5
- 208000019454 Feeding and Eating disease Diseases 0.000 claims description 5
- 208000014540 Functional gastrointestinal disease Diseases 0.000 claims description 5
- 206010019233 Headaches Diseases 0.000 claims description 5
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 5
- 206010065390 Inflammatory pain Diseases 0.000 claims description 5
- 206010026749 Mania Diseases 0.000 claims description 5
- 208000008589 Obesity Diseases 0.000 claims description 5
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims description 5
- 201000004681 Psoriasis Diseases 0.000 claims description 5
- 206010039085 Rhinitis allergic Diseases 0.000 claims description 5
- 206010046543 Urinary incontinence Diseases 0.000 claims description 5
- 206010046851 Uveitis Diseases 0.000 claims description 5
- 230000001154 acute effect Effects 0.000 claims description 5
- 208000005298 acute pain Diseases 0.000 claims description 5
- 208000026935 allergic disease Diseases 0.000 claims description 5
- 201000010105 allergic rhinitis Diseases 0.000 claims description 5
- 230000036506 anxiety Effects 0.000 claims description 5
- 208000006673 asthma Diseases 0.000 claims description 5
- 230000036772 blood pressure Effects 0.000 claims description 5
- 201000007637 bowel dysfunction Diseases 0.000 claims description 5
- 208000018912 cluster headache syndrome Diseases 0.000 claims description 5
- 208000010877 cognitive disease Diseases 0.000 claims description 5
- 235000014632 disordered eating Nutrition 0.000 claims description 5
- 206010014599 encephalitis Diseases 0.000 claims description 5
- 231100000869 headache Toxicity 0.000 claims description 5
- 230000009610 hypersensitivity Effects 0.000 claims description 5
- 230000002757 inflammatory effect Effects 0.000 claims description 5
- 230000007803 itching Effects 0.000 claims description 5
- 150000002632 lipids Chemical class 0.000 claims description 5
- 230000027939 micturition Effects 0.000 claims description 5
- 201000006417 multiple sclerosis Diseases 0.000 claims description 5
- 208000010125 myocardial infarction Diseases 0.000 claims description 5
- 235000020824 obesity Nutrition 0.000 claims description 5
- 201000008482 osteoarthritis Diseases 0.000 claims description 5
- 210000002307 prostate Anatomy 0.000 claims description 5
- 230000000241 respiratory effect Effects 0.000 claims description 5
- 201000000980 schizophrenia Diseases 0.000 claims description 5
- 208000019116 sleep disease Diseases 0.000 claims description 5
- 208000020431 spinal cord injury Diseases 0.000 claims description 5
- VAGQFUYFCXXJAL-LYTYMJBXSA-N (2r)-2-[5-[[2-(1-adamantyl)acetyl]amino]-6-chloro-1-oxoisoquinolin-2-yl]propanamide Chemical compound C1C(C2)CC(C3)CC2CC13CC(=O)NC1=C2C=CN([C@@H](C(N)=O)C)C(=O)C2=CC=C1Cl VAGQFUYFCXXJAL-LYTYMJBXSA-N 0.000 claims description 4
- VIFCIENBDYQQDX-LLVKDONJSA-N (2r)-2-[6-chloro-1-oxo-5-[[2-[4-(trifluoromethyl)phenyl]acetyl]amino]isoquinolin-2-yl]propanamide Chemical compound ClC1=CC=C2C(=O)N([C@@H](C(N)=O)C)C=CC2=C1NC(=O)CC1=CC=C(C(F)(F)F)C=C1 VIFCIENBDYQQDX-LLVKDONJSA-N 0.000 claims description 4
- OPGCMPGPBPRTCR-SNVBAGLBSA-N (2r)-2-[6-chloro-5-[[2-(4-chloro-2-fluorophenyl)acetyl]amino]-1-oxoisoquinolin-2-yl]propanamide Chemical compound ClC1=CC=C2C(=O)N([C@@H](C(N)=O)C)C=CC2=C1NC(=O)CC1=CC=C(Cl)C=C1F OPGCMPGPBPRTCR-SNVBAGLBSA-N 0.000 claims description 4
- MZMRGDSURPETPD-SNVBAGLBSA-N (2r)-2-[6-chloro-5-[[2-[2-fluoro-3-(trifluoromethyl)phenyl]acetyl]amino]-1-oxoisoquinolin-2-yl]propanamide Chemical compound ClC1=CC=C2C(=O)N([C@@H](C(N)=O)C)C=CC2=C1NC(=O)CC1=CC=CC(C(F)(F)F)=C1F MZMRGDSURPETPD-SNVBAGLBSA-N 0.000 claims description 4
- KGUURNWYZWNORB-GFCCVEGCSA-N (2r)-2-[6-methoxy-1-oxo-5-[[2-[4-(trifluoromethyl)phenyl]acetyl]amino]isoquinolin-2-yl]propanamide Chemical compound COC1=CC=C(C(N([C@H](C)C(N)=O)C=C2)=O)C2=C1NC(=O)CC1=CC=C(C(F)(F)F)C=C1 KGUURNWYZWNORB-GFCCVEGCSA-N 0.000 claims description 4
- VIFCIENBDYQQDX-NSHDSACASA-N (2s)-2-[6-chloro-1-oxo-5-[[2-[4-(trifluoromethyl)phenyl]acetyl]amino]isoquinolin-2-yl]propanamide Chemical compound ClC1=CC=C2C(=O)N([C@H](C(N)=O)C)C=CC2=C1NC(=O)CC1=CC=C(C(F)(F)F)C=C1 VIFCIENBDYQQDX-NSHDSACASA-N 0.000 claims description 4
- WKSFDYRQJMJNFR-NWDGAFQWSA-N (2s)-n-[2-[(2r)-1-amino-1-oxopropan-2-yl]-6-chloro-1-oxoisoquinolin-5-yl]-2-(4-chlorophenyl)propanamide Chemical compound C1([C@@H](C(=O)NC=2C3=C(C(N([C@H](C)C(N)=O)C=C3)=O)C=CC=2Cl)C)=CC=C(Cl)C=C1 WKSFDYRQJMJNFR-NWDGAFQWSA-N 0.000 claims description 4
- UFSZNGPKJWFSHR-CYBMUJFWSA-N 2-(4-chloro-3-fluorophenyl)-n-[2-[(2r)-1-hydroxypropan-2-yl]-6-methyl-1-oxoisoquinolin-5-yl]acetamide Chemical compound CC1=CC=C2C(=O)N([C@@H](CO)C)C=CC2=C1NC(=O)CC1=CC=C(Cl)C(F)=C1 UFSZNGPKJWFSHR-CYBMUJFWSA-N 0.000 claims description 4
- NNKBOZOTRMTPFO-LLVKDONJSA-N 2-(4-chloro-3-fluorophenyl)-n-[6-chloro-2-[(2r)-1-hydroxypropan-2-yl]-1-oxoisoquinolin-5-yl]acetamide Chemical compound ClC1=CC=C2C(=O)N([C@@H](CO)C)C=CC2=C1NC(=O)CC1=CC=C(Cl)C(F)=C1 NNKBOZOTRMTPFO-LLVKDONJSA-N 0.000 claims description 4
- OHYAXGAMZSGPOJ-UHFFFAOYSA-N 2-[2-fluoro-3-(trifluoromethyl)phenyl]-n-[2-(2-hydroxyethyl)-6-(2-hydroxyethylamino)-1-oxoisoquinolin-5-yl]acetamide Chemical compound OCCNC1=CC=C(C(N(CCO)C=C2)=O)C2=C1NC(=O)CC1=CC=CC(C(F)(F)F)=C1F OHYAXGAMZSGPOJ-UHFFFAOYSA-N 0.000 claims description 4
- LKZDPAFXWXYVCK-UHFFFAOYSA-N 2-[2-fluoro-3-(trifluoromethyl)phenyl]-n-[2-(2-hydroxyethyl)-6-methyl-1-oxoisoquinolin-5-yl]acetamide Chemical compound CC1=CC=C(C(N(CCO)C=C2)=O)C2=C1NC(=O)CC1=CC=CC(C(F)(F)F)=C1F LKZDPAFXWXYVCK-UHFFFAOYSA-N 0.000 claims description 4
- VSGLANORJMNZRC-CYBMUJFWSA-N 2-[2-fluoro-3-(trifluoromethyl)phenyl]-n-[2-[(2r)-1-hydroxypropan-2-yl]-6-methyl-1-oxoisoquinolin-5-yl]acetamide Chemical compound CC1=CC=C2C(=O)N([C@@H](CO)C)C=CC2=C1NC(=O)CC1=CC=CC(C(F)(F)F)=C1F VSGLANORJMNZRC-CYBMUJFWSA-N 0.000 claims description 4
- BDROBZBNYQZUKM-GFCCVEGCSA-N 2-[3-fluoro-4-(trifluoromethyl)phenyl]-n-[2-[(2r)-1-hydroxypropan-2-yl]-6-methoxy-1-oxoisoquinolin-5-yl]acetamide Chemical compound COC1=CC=C(C(N([C@H](C)CO)C=C2)=O)C2=C1NC(=O)CC1=CC=C(C(F)(F)F)C(F)=C1 BDROBZBNYQZUKM-GFCCVEGCSA-N 0.000 claims description 4
- JECILOFRRYCNDH-CYBMUJFWSA-N 2-[3-fluoro-4-(trifluoromethyl)phenyl]-n-[2-[(2r)-1-hydroxypropan-2-yl]-6-methyl-1-oxoisoquinolin-5-yl]acetamide Chemical compound CC1=CC=C2C(=O)N([C@@H](CO)C)C=CC2=C1NC(=O)CC1=CC=C(C(F)(F)F)C(F)=C1 JECILOFRRYCNDH-CYBMUJFWSA-N 0.000 claims description 4
- QGYFHOFGDBIVEE-HNNXBMFYSA-N 2-[3-fluoro-4-(trifluoromethyl)phenyl]-n-[6-methyl-1-oxo-2-[(3s)-pyrrolidin-3-yl]isoquinolin-5-yl]acetamide Chemical compound C=1C=C(C(F)(F)F)C(F)=CC=1CC(=O)NC=1C(C)=CC=C(C2=O)C=1C=CN2[C@H]1CCNC1 QGYFHOFGDBIVEE-HNNXBMFYSA-N 0.000 claims description 4
- UTSFTJWRTXSFSI-CYBMUJFWSA-N 2-[4-fluoro-3-(trifluoromethyl)phenyl]-n-[2-[(2r)-1-hydroxypropan-2-yl]-6-methyl-1-oxoisoquinolin-5-yl]acetamide Chemical compound CC1=CC=C2C(=O)N([C@@H](CO)C)C=CC2=C1NC(=O)CC1=CC=C(F)C(C(F)(F)F)=C1 UTSFTJWRTXSFSI-CYBMUJFWSA-N 0.000 claims description 4
- BHWBPMXJZHATJD-HNNXBMFYSA-N 2-[4-fluoro-3-(trifluoromethyl)phenyl]-n-[6-methyl-1-oxo-2-[(3s)-pyrrolidin-3-yl]isoquinolin-5-yl]acetamide Chemical compound C=1C=C(F)C(C(F)(F)F)=CC=1CC(=O)NC=1C(C)=CC=C(C2=O)C=1C=CN2[C@H]1CCNC1 BHWBPMXJZHATJD-HNNXBMFYSA-N 0.000 claims description 4
- 208000036110 Neuroinflammatory disease Diseases 0.000 claims description 4
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 claims description 4
- 201000009961 allergic asthma Diseases 0.000 claims description 4
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 4
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 4
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 4
- AFSOBVSIITWGAF-CQSZACIVSA-N n-[2-[(2r)-1-hydroxypropan-2-yl]-6-methyl-1-oxoisoquinolin-5-yl]-2-[4-(trifluoromethyl)phenyl]acetamide Chemical compound CC1=CC=C2C(=O)N([C@@H](CO)C)C=CC2=C1NC(=O)CC1=CC=C(C(F)(F)F)C=C1 AFSOBVSIITWGAF-CQSZACIVSA-N 0.000 claims description 4
- IZEFXOBBYMQCBC-UHFFFAOYSA-N n-[6-chloro-2-(2-hydroxyethyl)-1-oxoisoquinolin-5-yl]-2-(3,4-dichlorophenyl)acetamide Chemical compound ClC1=CC=C2C(=O)N(CCO)C=CC2=C1NC(=O)CC1=CC=C(Cl)C(Cl)=C1 IZEFXOBBYMQCBC-UHFFFAOYSA-N 0.000 claims description 4
- XJRFFZIYWHIBPY-UHFFFAOYSA-N n-[6-chloro-2-(2-hydroxyethyl)-1-oxoisoquinolin-5-yl]-2-[2-fluoro-3-(trifluoromethyl)phenyl]acetamide Chemical compound ClC1=CC=C2C(=O)N(CCO)C=CC2=C1NC(=O)CC1=CC=CC(C(F)(F)F)=C1F XJRFFZIYWHIBPY-UHFFFAOYSA-N 0.000 claims description 4
- ZXOKHTSAKAOOLZ-UHFFFAOYSA-N n-[6-chloro-2-(2-hydroxyethyl)-1-oxoisoquinolin-5-yl]-2-[3-fluoro-4-(trifluoromethyl)phenyl]acetamide Chemical compound ClC1=CC=C2C(=O)N(CCO)C=CC2=C1NC(=O)CC1=CC=C(C(F)(F)F)C(F)=C1 ZXOKHTSAKAOOLZ-UHFFFAOYSA-N 0.000 claims description 4
- CUGAKOQXTULJDP-UHFFFAOYSA-N n-[6-chloro-2-(2-hydroxyethyl)-1-oxoisoquinolin-5-yl]-2-[4-fluoro-3-(trifluoromethyl)phenyl]acetamide Chemical compound ClC1=CC=C2C(=O)N(CCO)C=CC2=C1NC(=O)CC1=CC=C(F)C(C(F)(F)F)=C1 CUGAKOQXTULJDP-UHFFFAOYSA-N 0.000 claims description 4
- OTKCYGCETOSQLA-LLVKDONJSA-N n-[6-chloro-2-[(2r)-1-hydroxypropan-2-yl]-1-oxoisoquinolin-5-yl]-2-(3,4-dichlorophenyl)acetamide Chemical compound ClC1=CC=C2C(=O)N([C@@H](CO)C)C=CC2=C1NC(=O)CC1=CC=C(Cl)C(Cl)=C1 OTKCYGCETOSQLA-LLVKDONJSA-N 0.000 claims description 4
- LAUUQYWKAHXBPX-LLVKDONJSA-N n-[6-chloro-2-[(2r)-1-hydroxypropan-2-yl]-1-oxoisoquinolin-5-yl]-2-[2-fluoro-4-(trifluoromethyl)phenyl]acetamide Chemical compound ClC1=CC=C2C(=O)N([C@@H](CO)C)C=CC2=C1NC(=O)CC1=CC=C(C(F)(F)F)C=C1F LAUUQYWKAHXBPX-LLVKDONJSA-N 0.000 claims description 4
- FMOOSLMLRAUSBH-LLVKDONJSA-N n-[6-chloro-2-[(2r)-1-hydroxypropan-2-yl]-1-oxoisoquinolin-5-yl]-2-[3-fluoro-4-(trifluoromethyl)phenyl]acetamide Chemical compound ClC1=CC=C2C(=O)N([C@@H](CO)C)C=CC2=C1NC(=O)CC1=CC=C(C(F)(F)F)C(F)=C1 FMOOSLMLRAUSBH-LLVKDONJSA-N 0.000 claims description 4
- SOXLIWHVZZQEKK-LLVKDONJSA-N n-[6-chloro-2-[(2r)-1-hydroxypropan-2-yl]-1-oxoisoquinolin-5-yl]-2-[4-fluoro-3-(trifluoromethyl)phenyl]acetamide Chemical compound ClC1=CC=C2C(=O)N([C@@H](CO)C)C=CC2=C1NC(=O)CC1=CC=C(F)C(C(F)(F)F)=C1 SOXLIWHVZZQEKK-LLVKDONJSA-N 0.000 claims description 4
- GFMGLRZDRMQUJJ-CYBMUJFWSA-N n-[6-cyclopropyl-2-[(2r)-1-hydroxypropan-2-yl]-1-oxoisoquinolin-5-yl]-2-[3-fluoro-4-(trifluoromethyl)phenyl]acetamide Chemical compound C1CC1C1=CC=C2C(=O)N([C@@H](CO)C)C=CC2=C1NC(=O)CC1=CC=C(C(F)(F)F)C(F)=C1 GFMGLRZDRMQUJJ-CYBMUJFWSA-N 0.000 claims description 4
- 230000003959 neuroinflammation Effects 0.000 claims description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 claims description 4
- 125000003396 thiol group Chemical group [H]S* 0.000 claims description 4
- AYLWRSUFLVTPDR-UHFFFAOYSA-N 2-[3-fluoro-4-(trifluoromethyl)phenyl]-n-[2-(2-hydroxyethyl)-6-methyl-1-oxoisoquinolin-5-yl]acetamide Chemical compound CC1=CC=C(C(N(CCO)C=C2)=O)C2=C1NC(=O)CC1=CC=C(C(F)(F)F)C(F)=C1 AYLWRSUFLVTPDR-UHFFFAOYSA-N 0.000 claims description 3
- 208000018569 Respiratory Tract disease Diseases 0.000 claims description 3
- 208000017169 kidney disease Diseases 0.000 claims description 3
- 201000006370 kidney failure Diseases 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 208000036273 reactive airway disease Diseases 0.000 claims description 3
- NPYWIUPZYUTEAK-GFCCVEGCSA-N (2r)-2-[5-[[2-[3-fluoro-4-(trifluoromethyl)phenyl]acetyl]amino]-6-methyl-1-oxoisoquinolin-2-yl]propanamide Chemical compound CC1=CC=C2C(=O)N([C@@H](C(N)=O)C)C=CC2=C1NC(=O)CC1=CC=C(C(F)(F)F)C(F)=C1 NPYWIUPZYUTEAK-GFCCVEGCSA-N 0.000 claims description 2
- YMFPTJMPYCNHKO-ASXFNGKXSA-N 2-(1-adamantyl)-n-[2-[(2r)-1-hydroxypropan-2-yl]-6-methyl-1-oxoisoquinolin-5-yl]acetamide Chemical compound C1C(C2)CC(C3)CC2CC13CC(=O)NC1=C2C=CN([C@@H](CO)C)C(=O)C2=CC=C1C YMFPTJMPYCNHKO-ASXFNGKXSA-N 0.000 claims description 2
- IXZKBFCFFLHLOH-CQSZACIVSA-N 2-[(2r)-1-hydroxypropan-2-yl]-6-methyl-1-oxo-n-[[3-(trifluoromethyl)phenyl]methyl]isoquinoline-5-carboxamide Chemical compound CC1=CC=C2C(=O)N([C@@H](CO)C)C=CC2=C1C(=O)NCC1=CC=CC(C(F)(F)F)=C1 IXZKBFCFFLHLOH-CQSZACIVSA-N 0.000 claims description 2
- GVNUVQYGCQUSSM-OAHLLOKOSA-N 2-[3-fluoro-4-(trifluoromethyl)phenyl]-n-[2-[(2r)-1-(3-hydroxyazetidin-1-yl)propan-2-yl]-6-methyl-1-oxoisoquinolin-5-yl]acetamide Chemical compound C([C@@H](C)N1C(C2=CC=C(C)C(NC(=O)CC=3C=C(F)C(=CC=3)C(F)(F)F)=C2C=C1)=O)N1CC(O)C1 GVNUVQYGCQUSSM-OAHLLOKOSA-N 0.000 claims description 2
- JECILOFRRYCNDH-ZDUSSCGKSA-N 2-[3-fluoro-4-(trifluoromethyl)phenyl]-n-[2-[(2s)-1-hydroxypropan-2-yl]-6-methyl-1-oxoisoquinolin-5-yl]acetamide Chemical compound CC1=CC=C2C(=O)N([C@H](CO)C)C=CC2=C1NC(=O)CC1=CC=C(C(F)(F)F)C(F)=C1 JECILOFRRYCNDH-ZDUSSCGKSA-N 0.000 claims description 2
- FFEPLNNDVFVTTR-QGZVFWFLSA-N 2-[3-fluoro-4-(trifluoromethyl)phenyl]-n-[6-methyl-1-oxo-2-[(2r)-1-piperazin-1-ylpropan-2-yl]isoquinolin-5-yl]acetamide Chemical compound C([C@@H](C)N1C(C2=CC=C(C)C(NC(=O)CC=3C=C(F)C(=CC=3)C(F)(F)F)=C2C=C1)=O)N1CCNCC1 FFEPLNNDVFVTTR-QGZVFWFLSA-N 0.000 claims description 2
- PSTNSIKFKNCGHB-CQSZACIVSA-N 2-[3-fluoro-4-(trifluoromethyl)phenyl]-n-[6-methyl-2-[(2r)-1-(methylamino)propan-2-yl]-1-oxoisoquinolin-5-yl]acetamide Chemical compound CC1=CC=C2C(=O)N([C@H](C)CNC)C=CC2=C1NC(=O)CC1=CC=C(C(F)(F)F)C(F)=C1 PSTNSIKFKNCGHB-CQSZACIVSA-N 0.000 claims description 2
- CSYHHBNQBKHTNI-UHFFFAOYSA-N 2-[3-fluoro-4-(trifluoromethyl)phenyl]-n-[6-methyl-2-[2-(methylamino)ethyl]-1-oxoisoquinolin-5-yl]acetamide Chemical compound CC1=CC=C2C(=O)N(CCNC)C=CC2=C1NC(=O)CC1=CC=C(C(F)(F)F)C(F)=C1 CSYHHBNQBKHTNI-UHFFFAOYSA-N 0.000 claims description 2
- AAMIKLACARMFCS-UHFFFAOYSA-N 2-[4-fluoro-3-(trifluoromethyl)phenyl]-n-[2-(2-hydroxyethyl)-6-methyl-1-oxoisoquinolin-5-yl]acetamide Chemical compound CC1=CC=C(C(N(CCO)C=C2)=O)C2=C1NC(=O)CC1=CC=C(F)C(C(F)(F)F)=C1 AAMIKLACARMFCS-UHFFFAOYSA-N 0.000 claims description 2
- ASENOMBGSSJKRC-MRXNPFEDSA-N 2-cycloheptyl-n-[2-[(2r)-1-hydroxypropan-2-yl]-6-methyl-1-oxoisoquinolin-5-yl]acetamide Chemical compound CC1=CC=C2C(=O)N([C@@H](CO)C)C=CC2=C1NC(=O)CC1CCCCCC1 ASENOMBGSSJKRC-MRXNPFEDSA-N 0.000 claims description 2
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims description 2
- OXONEBANLJOTOC-GFCCVEGCSA-N 6-chloro-2-[(2r)-1-hydroxypropan-2-yl]-1-oxo-n-[[2-(trifluoromethyl)phenyl]methyl]isoquinoline-5-carboxamide Chemical compound ClC1=CC=C2C(=O)N([C@@H](CO)C)C=CC2=C1C(=O)NCC1=CC=CC=C1C(F)(F)F OXONEBANLJOTOC-GFCCVEGCSA-N 0.000 claims description 2
- GBYDWBHRSCUQEX-GFCCVEGCSA-N 6-chloro-2-[(2r)-1-hydroxypropan-2-yl]-1-oxo-n-[[3-(trifluoromethyl)phenyl]methyl]isoquinoline-5-carboxamide Chemical compound ClC1=CC=C2C(=O)N([C@@H](CO)C)C=CC2=C1C(=O)NCC1=CC=CC(C(F)(F)F)=C1 GBYDWBHRSCUQEX-GFCCVEGCSA-N 0.000 claims description 2
- AGNFDSPQPAUSFK-LLVKDONJSA-N 6-chloro-2-[(2r)-1-hydroxypropan-2-yl]-1-oxo-n-[[6-(trifluoromethyl)pyridin-3-yl]methyl]isoquinoline-5-carboxamide Chemical compound ClC1=CC=C2C(=O)N([C@@H](CO)C)C=CC2=C1C(=O)NCC1=CC=C(C(F)(F)F)N=C1 AGNFDSPQPAUSFK-LLVKDONJSA-N 0.000 claims description 2
- STCKYUXIYJWHAM-SSDOTTSWSA-N 6-chloro-2-[(2r)-1-hydroxypropan-2-yl]-1-oxoisoquinoline-5-carboxylic acid Chemical compound ClC1=CC=C2C(=O)N([C@@H](CO)C)C=CC2=C1C(O)=O STCKYUXIYJWHAM-SSDOTTSWSA-N 0.000 claims description 2
- YKSYAQQQDHLPJI-CQSZACIVSA-N 6-chloro-n-(cycloheptylmethyl)-2-[(2r)-1-hydroxypropan-2-yl]-1-oxoisoquinoline-5-carboxamide Chemical compound ClC1=CC=C2C(=O)N([C@@H](CO)C)C=CC2=C1C(=O)NCC1CCCCCC1 YKSYAQQQDHLPJI-CQSZACIVSA-N 0.000 claims description 2
- BEMQUFQRXPAIGV-CQSZACIVSA-N 6-chloro-n-[(1-hydroxycycloheptyl)methyl]-2-[(2r)-1-hydroxypropan-2-yl]-1-oxoisoquinoline-5-carboxamide Chemical compound ClC1=CC=C2C(=O)N([C@@H](CO)C)C=CC2=C1C(=O)NCC1(O)CCCCCC1 BEMQUFQRXPAIGV-CQSZACIVSA-N 0.000 claims description 2
- FHXZVDBITWXWNE-CYBMUJFWSA-N 6-chloro-n-[(1-hydroxycyclohexyl)methyl]-2-[(2r)-1-hydroxypropan-2-yl]-1-oxoisoquinoline-5-carboxamide Chemical compound ClC1=CC=C2C(=O)N([C@@H](CO)C)C=CC2=C1C(=O)NCC1(O)CCCCC1 FHXZVDBITWXWNE-CYBMUJFWSA-N 0.000 claims description 2
- GTJKHIXCDWFPNM-ABWNMTHHSA-N 6-chloro-n-[(3-hydroxy-3-bicyclo[2.2.1]heptanyl)methyl]-2-[(2r)-1-hydroxypropan-2-yl]-1-oxoisoquinoline-5-carboxamide Chemical compound ClC1=CC=C2C(=O)N([C@@H](CO)C)C=CC2=C1C(=O)NCC1(O)C(C2)CCC2C1 GTJKHIXCDWFPNM-ABWNMTHHSA-N 0.000 claims description 2
- CAEONLAMIOORMA-GFCCVEGCSA-N 6-chloro-n-[(4,4-difluorocyclohexyl)methyl]-2-[(2r)-1-hydroxypropan-2-yl]-1-oxoisoquinoline-5-carboxamide Chemical compound ClC1=CC=C2C(=O)N([C@@H](CO)C)C=CC2=C1C(=O)NCC1CCC(F)(F)CC1 CAEONLAMIOORMA-GFCCVEGCSA-N 0.000 claims description 2
- PWBBZHNVXSPICS-LLVKDONJSA-N 6-chloro-n-[(4-chloro-3-fluorophenyl)methyl]-2-[(2r)-1-hydroxypropan-2-yl]-1-oxoisoquinoline-5-carboxamide Chemical compound ClC1=CC=C2C(=O)N([C@@H](CO)C)C=CC2=C1C(=O)NCC1=CC=C(Cl)C(F)=C1 PWBBZHNVXSPICS-LLVKDONJSA-N 0.000 claims description 2
- VTYGNFUYVGHQRP-LLVKDONJSA-N 6-chloro-n-[[3-fluoro-4-(trifluoromethyl)phenyl]methyl]-2-[(2r)-1-hydroxypropan-2-yl]-1-oxoisoquinoline-5-carboxamide Chemical compound ClC1=CC=C2C(=O)N([C@@H](CO)C)C=CC2=C1C(=O)NCC1=CC=C(C(F)(F)F)C(F)=C1 VTYGNFUYVGHQRP-LLVKDONJSA-N 0.000 claims description 2
- 125000002252 acyl group Chemical group 0.000 claims description 2
- 125000004442 acylamino group Chemical group 0.000 claims description 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 2
- 125000004947 alkyl aryl amino group Chemical group 0.000 claims description 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 2
- 125000004414 alkyl thio group Chemical group 0.000 claims description 2
- 125000002947 alkylene group Chemical group 0.000 claims description 2
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims description 2
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 2
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims description 2
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims description 2
- 125000004429 atom Chemical group 0.000 claims description 2
- 150000001540 azides Chemical class 0.000 claims description 2
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 238000006243 chemical reaction Methods 0.000 claims description 2
- 230000007812 deficiency Effects 0.000 claims description 2
- 230000003412 degenerative effect Effects 0.000 claims description 2
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 2
- 125000001072 heteroaryl group Chemical group 0.000 claims description 2
- 125000005553 heteroaryloxy group Chemical group 0.000 claims description 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 2
- 125000006217 methyl sulfide group Chemical group [H]C([H])([H])S* 0.000 claims description 2
- TWUJPPOAFORSHG-MRXNPFEDSA-N n-(cycloheptylmethyl)-2-[(2r)-1-hydroxypropan-2-yl]-6-methyl-1-oxoisoquinoline-5-carboxamide Chemical compound CC1=CC=C2C(=O)N([C@@H](CO)C)C=CC2=C1C(=O)NCC1CCCCCC1 TWUJPPOAFORSHG-MRXNPFEDSA-N 0.000 claims description 2
- KXQFFZDKVDPYRZ-MRXNPFEDSA-N n-[(1-hydroxycycloheptyl)methyl]-2-[(2r)-1-hydroxypropan-2-yl]-6-methyl-1-oxoisoquinoline-5-carboxamide Chemical compound CC1=CC=C2C(=O)N([C@@H](CO)C)C=CC2=C1C(=O)NCC1(O)CCCCCC1 KXQFFZDKVDPYRZ-MRXNPFEDSA-N 0.000 claims description 2
- BPPNPDKWLMZXDM-CYBMUJFWSA-N n-[(4-chloro-3-fluorophenyl)methyl]-2-[(2r)-1-hydroxypropan-2-yl]-6-methyl-1-oxoisoquinoline-5-carboxamide Chemical compound CC1=CC=C2C(=O)N([C@@H](CO)C)C=CC2=C1C(=O)NCC1=CC=C(Cl)C(F)=C1 BPPNPDKWLMZXDM-CYBMUJFWSA-N 0.000 claims description 2
- DUVRRTNJEKQIPG-UHFFFAOYSA-N n-[2-(1,3-dihydroxypropan-2-yl)-6-methyl-1-oxoisoquinolin-5-yl]-2-[3-fluoro-4-(trifluoromethyl)phenyl]acetamide Chemical compound CC1=CC=C(C(N(C(CO)CO)C=C2)=O)C2=C1NC(=O)CC1=CC=C(C(F)(F)F)C(F)=C1 DUVRRTNJEKQIPG-UHFFFAOYSA-N 0.000 claims description 2
- RKIHNKBYTUYHDG-CYBMUJFWSA-N n-[2-[(2r)-1-aminopropan-2-yl]-6-methyl-1-oxoisoquinolin-5-yl]-2-[3-fluoro-4-(trifluoromethyl)phenyl]acetamide Chemical compound CC1=CC=C2C(=O)N([C@@H](CN)C)C=CC2=C1NC(=O)CC1=CC=C(C(F)(F)F)C(F)=C1 RKIHNKBYTUYHDG-CYBMUJFWSA-N 0.000 claims description 2
- UTMNVXYOFWISHC-CQSZACIVSA-N n-[2-[(2r)-1-hydroxypropan-2-yl]-6-methyl-1-oxoisoquinolin-5-yl]-2-[3-(trifluoromethyl)phenyl]acetamide Chemical compound CC1=CC=C2C(=O)N([C@@H](CO)C)C=CC2=C1NC(=O)CC1=CC=CC(C(F)(F)F)=C1 UTMNVXYOFWISHC-CQSZACIVSA-N 0.000 claims description 2
- ITLBYFHASKQNFP-GFCCVEGCSA-N n-[6-chloro-2-[(2r)-1-hydroxypropan-2-yl]-1-oxoisoquinolin-5-yl]-2-[3-(trifluoromethyl)phenyl]acetamide Chemical compound ClC1=CC=C2C(=O)N([C@@H](CO)C)C=CC2=C1NC(=O)CC1=CC=CC(C(F)(F)F)=C1 ITLBYFHASKQNFP-GFCCVEGCSA-N 0.000 claims description 2
- XIGDTHFEXZYBMC-CQSZACIVSA-N n-[6-chloro-2-[(2r)-1-hydroxypropan-2-yl]-1-oxoisoquinolin-5-yl]-2-cycloheptylacetamide Chemical compound ClC1=CC=C2C(=O)N([C@@H](CO)C)C=CC2=C1NC(=O)CC1CCCCCC1 XIGDTHFEXZYBMC-CQSZACIVSA-N 0.000 claims description 2
- FMOOSLMLRAUSBH-NSHDSACASA-N n-[6-chloro-2-[(2s)-1-hydroxypropan-2-yl]-1-oxoisoquinolin-5-yl]-2-[3-fluoro-4-(trifluoromethyl)phenyl]acetamide Chemical compound ClC1=CC=C2C(=O)N([C@H](CO)C)C=CC2=C1NC(=O)CC1=CC=C(C(F)(F)F)C(F)=C1 FMOOSLMLRAUSBH-NSHDSACASA-N 0.000 claims description 2
- XOUBDCKHGLMWMZ-CYBMUJFWSA-N n-[[3-fluoro-4-(trifluoromethyl)phenyl]methyl]-2-[(2r)-1-hydroxypropan-2-yl]-6-methyl-1-oxoisoquinoline-5-carboxamide Chemical compound CC1=CC=C2C(=O)N([C@@H](CO)C)C=CC2=C1C(=O)NCC1=CC=C(C(F)(F)F)C(F)=C1 XOUBDCKHGLMWMZ-CYBMUJFWSA-N 0.000 claims description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 2
- 125000004043 oxo group Chemical group O=* 0.000 claims description 2
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims description 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N thioacetamide Natural products CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims description 2
- 235000019645 odor Nutrition 0.000 claims 1
- 238000000034 method Methods 0.000 description 16
- 241000124008 Mammalia Species 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 206010029240 Neuritis Diseases 0.000 description 5
- 230000007794 irritation Effects 0.000 description 4
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 206010003399 Arthropod bite Diseases 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- 208000001387 Causalgia Diseases 0.000 description 1
- 206010008334 Cervicobrachial syndrome Diseases 0.000 description 1
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- 208000021965 Glossopharyngeal Nerve disease Diseases 0.000 description 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
- 208000006877 Insect Bites and Stings Diseases 0.000 description 1
- 206010049949 Intercostal neuralgia Diseases 0.000 description 1
- 208000007914 Labor Pain Diseases 0.000 description 1
- 208000035945 Labour pain Diseases 0.000 description 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 1
- 208000002472 Morton Neuroma Diseases 0.000 description 1
- 208000020059 Morton neuralgia Diseases 0.000 description 1
- 206010068106 Occipital neuralgia Diseases 0.000 description 1
- 102100037602 P2X purinoceptor 7 Human genes 0.000 description 1
- 101710189965 P2X purinoceptor 7 Proteins 0.000 description 1
- 208000004983 Phantom Limb Diseases 0.000 description 1
- 206010056238 Phantom pain Diseases 0.000 description 1
- 206010036105 Polyneuropathy Diseases 0.000 description 1
- 206010036376 Postherpetic Neuralgia Diseases 0.000 description 1
- 208000008765 Sciatica Diseases 0.000 description 1
- 208000003589 Spider Bites Diseases 0.000 description 1
- 206010053509 Venomous bite Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000007885 bronchoconstriction Effects 0.000 description 1
- 229960002504 capsaicin Drugs 0.000 description 1
- 235000017663 capsaicin Nutrition 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 208000014439 complex regional pain syndrome type 2 Diseases 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 201000005442 glossopharyngeal neuralgia Diseases 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 201000009985 neuronitis Diseases 0.000 description 1
- 210000003254 palate Anatomy 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- IMACFCSSMIZSPP-UHFFFAOYSA-N phenacyl chloride Chemical compound ClCC(=O)C1=CC=CC=C1 IMACFCSSMIZSPP-UHFFFAOYSA-N 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 208000019629 polyneuritis Diseases 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000003491 tear gas Substances 0.000 description 1
- 210000001738 temporomandibular joint Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 206010044652 trigeminal neuralgia Diseases 0.000 description 1
Applications Claiming Priority (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US90604907P | 2007-03-09 | 2007-03-09 | |
| US91808607P | 2007-03-15 | 2007-03-15 | |
| US91826107P | 2007-03-15 | 2007-03-15 | |
| US91812307P | 2007-03-15 | 2007-03-15 | |
| US91826007P | 2007-03-15 | 2007-03-15 | |
| US838507P | 2007-12-20 | 2007-12-20 | |
| US838607P | 2007-12-20 | 2007-12-20 | |
| US837007P | 2007-12-20 | 2007-12-20 | |
| US1067208P | 2008-01-10 | 2008-01-10 | |
| PCT/US2008/003175 WO2008112205A1 (en) | 2007-03-09 | 2008-03-07 | Bicycloheteroaryl compounds as p2x7 modulators and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010520875A JP2010520875A (ja) | 2010-06-17 |
| JP2010520875A5 true JP2010520875A5 (OSRAM) | 2011-03-31 |
Family
ID=39759833
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009552762A Pending JP2010520875A (ja) | 2007-03-09 | 2008-03-07 | Ｐ２ｘ７調節因子としてのビシクロヘテロアリール化合物およびその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US8093265B2 (OSRAM) |
| EP (1) | EP2124562B1 (OSRAM) |
| JP (1) | JP2010520875A (OSRAM) |
| CN (1) | CN101686680B (OSRAM) |
| CA (1) | CA2680275C (OSRAM) |
| DK (1) | DK2124562T3 (OSRAM) |
| ES (1) | ES2576643T3 (OSRAM) |
| WO (1) | WO2008112205A1 (OSRAM) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2596532T3 (es) | 2006-03-16 | 2017-01-10 | Second Genome, Inc. | Compuestos de bicicloheteroarilo como moduladores de P2X7 y usos de los mismos |
| TWI464148B (zh) * | 2006-03-16 | 2014-12-11 | Evotec Us Inc | 作為ｐ２ｘ7調節劑之雙環雜芳基化合物與其用途 |
| EP2001474B1 (en) | 2006-03-16 | 2016-03-09 | Second Genome, Inc. | Bicycloheteroaryl compounds as p2x7 modulators and uses thereof |
| SI2049478T1 (sl) * | 2006-07-06 | 2012-08-31 | Glaxo Group Ltd | Substituirani N-fenilmetil-5-okso-prolin-2-amidi kot antagonisti receptorja P2X7 in postopki za njihovo uporabo |
| US8212723B2 (en) * | 2008-08-27 | 2012-07-03 | Qualcomm Incorporated | Method and apparatus for determining at a predetermined granularity the direction and range of a transmitting mobile device |
| MX2014000894A (es) | 2011-07-22 | 2014-02-27 | Actelion Pharmaceuticals Ltd | Derivados de amidas heterociclicas como antagonistas de receptores p2x7. |
| BR112014017735B1 (pt) | 2012-01-20 | 2022-06-28 | Idorsia Pharmaceuticals Ltd | Compostos derivados de amida heterocíclicos como antagonistas do receptor de p2x7, composição farmacêutica, e, uso de um composto |
| EP2931717B1 (en) | 2012-12-12 | 2016-12-07 | Actelion Pharmaceuticals Ltd. | Indole carboxamide derivatives as p2x7 receptor antagonists |
| CA2891499C (en) | 2012-12-18 | 2021-07-06 | Actelion Pharmaceuticals Ltd | Indole carboxamide derivatives as p2x7 receptor antagonists |
| CN104918617B (zh) | 2013-01-22 | 2017-05-10 | 埃科特莱茵药品有限公司 | 作为p2x7受体拮抗剂的杂环酰胺衍生物 |
| JP6282017B2 (ja) | 2013-01-22 | 2018-02-21 | イドーシア ファーマシューティカルズ リミテッドＩｄｏｒｓｉａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ | Ｐ２ｘ７受容体アンタゴニストとしての複素環アミド誘導体 |
| US9399623B2 (en) * | 2014-06-05 | 2016-07-26 | Merck Patent Gmbh | Quinoline derivatives and their use in neurodegenerative diseases |
| TWI825637B (zh) | 2021-03-31 | 2023-12-11 | 美商輝瑞股份有限公司 | 啶－１，６（２ｈ，７ｈ）－二酮 |
| WO2025057074A1 (en) * | 2023-09-13 | 2025-03-20 | Suven Life Sciences Limited | N-aryl benzamide derivatives as p2x7 receptor antagonists |
Family Cites Families (105)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US588736A (en) * | 1897-08-24 | Egg-tester | ||
| FR2450E (fr) | 1903-02-09 | 1904-04-07 | Sulzer Freres Soc | Palier pour pompes et autres machines analogues |
| DE2343984A1 (de) | 1973-08-31 | 1975-03-13 | Hoechst Ag | Wasserunloesliche disazomethinfarbstoffe, verfahren zu ihrer herstellung und ihre verwendung |
| US3950343A (en) | 1973-11-06 | 1976-04-13 | Ayerst, Mckenna And Harrison Ltd. | Pyrroloisoquinoline derivatives |
| US3900477A (en) | 1973-11-06 | 1975-08-19 | Ayerst Mckenna & Harrison | 5-amino-and 5-hydrazinodihydropyrroloisoquinoline derivatives |
| SU749832A1 (ru) | 1978-03-24 | 1980-07-23 | Предприятие П/Я М-5885 | Способ получени амино- -оксифенантридонов |
| GB2044254B (en) | 1979-01-26 | 1983-01-26 | Wyeth John & Brother Ltd | Piperidine derivatives |
| EP0093488A3 (en) | 1982-03-18 | 1984-05-23 | Beecham Group Plc | Nortropyl benzopyrrolinone compounds, process for their preparation and pharmaceutical compositions containing them |
| DE3368061D1 (en) | 1982-05-11 | 1987-01-15 | Beecham Group Plc | Azabicycloalkane derivatives, their preparation and medicaments containing them |
| EP0101641A3 (en) | 1982-07-22 | 1984-03-28 | Beecham Group Plc | Sulfonylamino-aza-bicyclo-alkyl derivatives |
| JPH0731405B2 (ja) | 1986-05-02 | 1995-04-10 | キヤノン株式会社 | 電子写真感光体 |
| JP2699511B2 (ja) | 1988-01-29 | 1998-01-19 | 武田薬品工業株式会社 | 置換アミン類 |
| US4897391A (en) | 1988-06-17 | 1990-01-30 | Schering Corporation | Tricyclic anti-allergy, antiinflammatory and anti-hyperproliferative compounds |
| US5776963A (en) | 1989-05-19 | 1998-07-07 | Hoechst Marion Roussel, Inc. | 3-(heteroaryl)-1- (2,3-dihydro-1h-isoindol-2-yl)alkyl!pyrrolidines and 3-(heteroaryl)-1- (2,3-dihydro-1h-indol-1-yl)alkyl!pyrrolidines and related compounds and their therapeutic untility |
| GB8926560D0 (en) | 1989-11-24 | 1990-01-17 | Zambeletti Spa L | Pharmaceuticals |
| US5140023A (en) | 1990-04-27 | 1992-08-18 | G. D. Searle & Co. | Azatetracycle compounds |
| HU213136B (en) | 1990-08-14 | 1997-02-28 | Kyorin Seiyaku Kk | Process for producing fluoroethyl camptothecin derivatives and pharmaceutical compositions containing them |
| KR920008026A (ko) | 1990-10-24 | 1992-05-27 | 오노 화아마슈티칼 캄파니 리미팃드 | 이소퀴놀리논 유도체 또는 이의 무독성 산부가염 또는 이의 수화물, 이의 제조방법 및 이를 포함하는 약제 조성물 |
| JPH04270273A (ja) | 1991-02-25 | 1992-09-25 | Kyorin Pharmaceut Co Ltd | チアゾリジン−２，４−ジオン誘導体とその塩及びその製造法 |
| EP0502575A1 (en) | 1991-03-06 | 1992-09-09 | Merck & Co. Inc. | Substituted 1-(2H)-isoquinolinones |
| AU1532492A (en) | 1991-04-18 | 1992-11-17 | Dr. Lo Zambeletti S.P.A. | Use of heterocyclic compounds for the treatment of inflammatory pain |
| US5491148A (en) | 1991-04-26 | 1996-02-13 | Syntex (U.S.A.) Inc. | Isoquinolinone and dihydroisoquinolinone 5-HT3 receptor antagonists |
| DE69209576T4 (de) | 1991-05-10 | 1997-01-30 | Takeda Chemical Industries Ltd | Pyridinderivate, deren Herstellung und Anwendung |
| GB9122859D0 (en) | 1991-10-28 | 1991-12-11 | Smithkline Beecham Plc | Novel compounds |
| US5272158A (en) | 1991-10-29 | 1993-12-21 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
| JPH06295078A (ja) | 1992-04-24 | 1994-10-21 | Canon Inc | 電子写真感光体、該電子写真感光体を備えた電子写真装置並びにファクシミリ |
| US5840903A (en) | 1992-07-27 | 1998-11-24 | G. D. Searle & Co. | 4-aminomethyl-1-azaadamantane derived benzamides |
| US5354757A (en) | 1992-12-15 | 1994-10-11 | G. D. Searle & Co. | Azanoradamantanes |
| JPH08511538A (ja) | 1993-06-09 | 1996-12-03 | スミスクライン・ビーチャム・コーポレイション | 二環式フィブリノゲン拮抗物質 |
| DE4345266C2 (de) | 1993-10-04 | 1996-12-19 | Luitpold Pharma Gmbh | Heterocyclische Carbamate, Verfahren zu ihrer Herstellung und Arzneimittel |
| CA2155662A1 (en) | 1993-12-27 | 1995-07-06 | Fumihiro Ozaki | Anthranilic acid derivative |
| US5530018A (en) | 1994-02-04 | 1996-06-25 | G. D. Searle & Co. | Meso-azanoradamantanes |
| GB9409150D0 (en) | 1994-05-09 | 1994-06-29 | Black James Foundation | Cck and gastrin receptor ligands |
| US5500442A (en) | 1994-06-10 | 1996-03-19 | American Home Products Corporation | Cyclobut-3-ene-1,2-dione derivatives as smooth muscle relaxants |
| US5644144A (en) * | 1994-09-23 | 1997-07-01 | Advanced Micro Devices, Inc. | Device and method for programming a logic level within an integrated circuit using multiple mask layers |
| US5631280A (en) | 1995-03-29 | 1997-05-20 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| JP2000501063A (ja) | 1995-06-29 | 2000-02-02 | メルク エンド カンパニー インコーポレーテッド | ファルネシル−タンパク質トランスフェラーゼ阻害剤の組み合わせ |
| US5723411A (en) | 1995-10-31 | 1998-03-03 | E. I. Du Pont De Nemours And Company | Herbicidal pyridazinones |
| JP3285746B2 (ja) | 1995-11-24 | 2002-05-27 | 株式会社資生堂 | フェニレンジアミン誘導体及びラジカルスカベンジャー、脳梗塞抑制剤、脳浮腫抑制剤 |
| US5756518A (en) | 1996-04-02 | 1998-05-26 | Kowa Co., Ltd. | Phenylene derivatives |
| AU2980797A (en) | 1996-06-11 | 1998-01-07 | Yoshitomi Pharmaceutical Industries, Ltd. | Fused heterocyclic compounds and medicinal uses thereof |
| WO1998004247A1 (en) | 1996-07-25 | 1998-02-05 | Biogen, Inc. | Cell adhesion inhibitors |
| US6429212B1 (en) | 1996-08-16 | 2002-08-06 | Ishihara Sangyo Kaisha Ltd. | Medicinal composition |
| DE19650975A1 (de) | 1996-12-09 | 1998-06-10 | Basf Ag | Neue heterocyclisch substituierte Benzamide und deren Anwendung |
| DE19653645A1 (de) | 1996-12-20 | 1998-06-25 | Hoechst Ag | Vitronectin - Rezeptorantagonisten, deren Herstellung sowie deren Verwendung |
| DE19653647A1 (de) | 1996-12-20 | 1998-06-25 | Hoechst Ag | Vitronectin - Rezeptorantagonisten, deren Herstellung sowie deren Verwendung |
| US6262068B1 (en) | 1997-02-21 | 2001-07-17 | Bristol-Myers Squibb Company | Lactam derivatives as antiarrhythmic agents |
| PT877019E (pt) | 1997-05-09 | 2002-05-31 | Hoechst Ag | Acidos diaminocarboxilicos substituidos |
| TW544448B (en) | 1997-07-11 | 2003-08-01 | Novartis Ag | Pyridine derivatives |
| DK1023291T3 (da) | 1997-10-07 | 2004-10-04 | Ortho Mcneil Pharm Inc | Dipyridoimidazolderivater, som er egnet til behandling af lidelser i centralnervesystemet |
| CA2307030A1 (en) | 1997-10-24 | 1999-05-06 | Mervyn Thompson | Substituted isoquinoline derivatives and their use as anticonvulsants |
| JP3337992B2 (ja) | 1997-11-04 | 2002-10-28 | ファイザー製薬株式会社 | ５−置換ピコリン酸化合物及びその製造方法 |
| SE9704545D0 (sv) | 1997-12-05 | 1997-12-05 | Astra Pharma Prod | Novel compounds |
| SE9704546D0 (sv) | 1997-12-05 | 1997-12-05 | Astra Pharma Prod | Novel compounds |
| JPH11171774A (ja) | 1997-12-05 | 1999-06-29 | Kyowa Hakko Kogyo Co Ltd | 血球増多剤 |
| SE9704544D0 (sv) | 1997-12-05 | 1997-12-05 | Astra Pharma Prod | Novel compounds |
| AU1887999A (en) | 1998-01-29 | 1999-08-16 | Dr. Reddy's Research Foundation | Novel alkanoic acids and their use in medicine, process for their preparation and pharmaceutical compositions containing them |
| WO1999059975A1 (en) | 1998-05-15 | 1999-11-25 | Guilford Pharmaceuticals Inc. | Fused tricyclic compounds which inhibit parp activity |
| GB9817424D0 (en) | 1998-08-11 | 1998-10-07 | Smithkline Beecham Plc | Novel compounds |
| SE9901875D0 (sv) | 1999-05-25 | 1999-05-25 | Astra Pharma Prod | Novel compounds |
| GB9915995D0 (en) | 1999-07-09 | 1999-09-08 | Ahmed S | Non-steroidal sulphamate compounds for use as oestrone sulphatase inhibitors |
| JP2003506388A (ja) | 1999-08-04 | 2003-02-18 | アイカゲン インコーポレイテッド | 疼痛および不安症を処置または予防するための方法 |
| EP1208085B1 (en) | 1999-08-04 | 2007-12-05 | Icagen, Inc. | Benzanilides as potassium channel openers |
| GB9919411D0 (en) | 1999-08-18 | 1999-10-20 | Zeneca Ltd | Chemical compounds |
| AU7314200A (en) | 1999-09-17 | 2001-04-24 | Yamanouchi Pharmaceutical Co., Ltd. | Benzimidazole derivatives |
| JP2001172258A (ja) | 1999-12-17 | 2001-06-26 | Sumitomo Pharmaceut Co Ltd | 神経網膜変性疾患の治療薬 |
| SE9904652D0 (sv) | 1999-12-17 | 1999-12-17 | Astra Pharma Prod | Novel Compounds |
| AU2001239725A1 (en) | 2000-01-13 | 2001-07-24 | Tularik, Inc. | Antibacterial agents |
| GB0005366D0 (en) | 2000-03-06 | 2000-04-26 | Xenova Ltd | Pharmaceutical compounds |
| US6469026B2 (en) | 2000-03-24 | 2002-10-22 | Millennium Pharmaceuticals, Inc. | Isoquinolone inhibitors of factor Xa |
| WO2002006240A1 (en) | 2000-07-13 | 2002-01-24 | Guilford Pharmaceuticals Inc. | Substituted 4,9-dihydrocyclopenta[imn] phenanthridine-5-ones, derivatives thereof and their uses |
| US6603013B2 (en) | 2000-07-17 | 2003-08-05 | Merck & Co., Inc. | Heterogeneously catalyzed process for cross coupling alkenyl halides with boronic acids |
| US20040122223A1 (en) | 2001-02-07 | 2004-06-24 | Davis Jeremy Martin | Non-natural nucleotides and dinucleotides |
| JP2002338837A (ja) | 2001-05-16 | 2002-11-27 | Fuji Photo Film Co Ltd | 新規化合物、色素、インク組成物、インクジェット用インク、インクジェット記録方法、及び熱転写色素 |
| WO2002094790A1 (en) | 2001-05-23 | 2002-11-28 | Mitsubishi Pharma Corporation | Fused heterocyclic compound and medicinal use thereof |
| CA2455181C (en) | 2001-08-01 | 2010-04-06 | Merck & Co., Inc. | Benzimidazo[4,5-f]isoquinolinone derivatives |
| US7074805B2 (en) | 2002-02-20 | 2006-07-11 | Abbott Laboratories | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor |
| CA2476936A1 (en) | 2002-02-20 | 2003-08-28 | Chih-Hung Lee | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor |
| GB0206876D0 (en) | 2002-03-22 | 2002-05-01 | Merck Sharp & Dohme | Therapeutic agents |
| AU2003219088A1 (en) | 2002-03-26 | 2003-10-08 | Zentopharm Gmbh | Fredericamycin derivatives |
| DE10215316C1 (de) | 2002-04-02 | 2003-12-18 | Schering Ag | Chinolin- und Isochinolin-Derivate, ein pharmazeutisches Mittel und ihre Verwendung als Entzündungshemmer |
| RS95404A (sr) | 2002-05-03 | 2006-10-27 | Schering Aktiengesellschaft | Tiazolidinoni i njihova primena kao inhibitora polo like kinaze |
| AU2003281623B8 (en) | 2002-07-22 | 2009-06-11 | Asahi Kasei Pharma Corporation | 5-substituted isoquinoline derivative |
| DE10238865A1 (de) | 2002-08-24 | 2004-03-11 | Boehringer Ingelheim International Gmbh | Neue Carbonsäureamid-Verbindungen mit MCH-antagonistischer Wirkung, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| JP2004203813A (ja) | 2002-12-26 | 2004-07-22 | Tokuyama Corp | クロメン化合物 |
| PA8591801A1 (es) | 2002-12-31 | 2004-07-26 | Pfizer Prod Inc | Inhibidores benzamidicos del receptor p2x7. |
| SG2012000667A (en) | 2003-01-08 | 2015-03-30 | Univ Washington | Antibacterial agents |
| TW200503994A (en) | 2003-01-24 | 2005-02-01 | Novartis Ag | Organic compounds |
| CA2514940A1 (en) | 2003-02-03 | 2004-08-19 | Janssen Pharmaceutica N.V. | Quinoline-derived amide modulators of vanilloid vr1 receptor |
| US20060211724A1 (en) | 2003-04-28 | 2006-09-21 | Verschueren Gaston W | Hiv integrase inhibitors |
| JP4731468B2 (ja) | 2003-05-12 | 2011-07-27 | ファイザー・プロダクツ・インク | Ｐ２ｘ７受容体のベンズアミド阻害剤 |
| CN1566099A (zh) | 2003-06-13 | 2005-01-19 | 中国科学院上海药物研究所 | 异喹啉－1,3,4－三酮类化合物、制备方法及其用途 |
| WO2004113345A1 (ja) | 2003-06-20 | 2004-12-29 | Japan Tobacco Inc. | 縮合ピロール化合物及びその医薬用途 |
| US7390820B2 (en) | 2003-08-25 | 2008-06-24 | Amgen Inc. | Substituted quinolinone derivatives and methods of use |
| JP4667384B2 (ja) | 2003-10-07 | 2011-04-13 | レノビス， インコーポレイテッド | イオンチャネルリガンドとしてのアミド誘導体および薬学的組成物、ならびにこれらを使用する方法 |
| US7491794B2 (en) | 2003-10-14 | 2009-02-17 | Intermune, Inc. | Macrocyclic compounds as inhibitors of viral replication |
| TW200530235A (en) | 2003-12-24 | 2005-09-16 | Renovis Inc | Bicycloheteroarylamine compounds as ion channel ligands and uses thereof |
| JP2005232175A (ja) | 2004-01-21 | 2005-09-02 | Asahi Kasei Pharma Kk | ５−置換イソキノリン医薬 |
| EP1737414A2 (en) | 2004-01-23 | 2007-01-03 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments of inflammatory and neuropatic pain |
| US7576099B2 (en) | 2005-02-28 | 2009-08-18 | Renovis, Inc. | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same |
| US7297700B2 (en) * | 2005-03-24 | 2007-11-20 | Renovis, Inc. | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof |
| TWI464148B (zh) * | 2006-03-16 | 2014-12-11 | Evotec Us Inc | 作為ｐ２ｘ7調節劑之雙環雜芳基化合物與其用途 |
| ES2596532T3 (es) * | 2006-03-16 | 2017-01-10 | Second Genome, Inc. | Compuestos de bicicloheteroarilo como moduladores de P2X7 y usos de los mismos |
| EP2001474B1 (en) * | 2006-03-16 | 2016-03-09 | Second Genome, Inc. | Bicycloheteroaryl compounds as p2x7 modulators and uses thereof |
| WO2007109154A2 (en) * | 2006-03-16 | 2007-09-27 | Renovis, Inc. | Bicycloheteroaryl compounds as p2x7 modulators and uses thereof |
-
2008
- 2008-03-07 DK DK08726672.2T patent/DK2124562T3/en active
- 2008-03-07 ES ES08726672.2T patent/ES2576643T3/es active Active
- 2008-03-07 EP EP08726672.2A patent/EP2124562B1/en not_active Not-in-force
- 2008-03-07 WO PCT/US2008/003175 patent/WO2008112205A1/en not_active Ceased
- 2008-03-07 US US12/075,111 patent/US8093265B2/en not_active Expired - Fee Related
- 2008-03-07 CA CA2680275A patent/CA2680275C/en not_active Expired - Fee Related
- 2008-03-07 JP JP2009552762A patent/JP2010520875A/ja active Pending
- 2008-03-07 CN CN200880014110.6A patent/CN101686680B/zh active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010520875A5 (OSRAM) | ||
| JP2008534511A5 (OSRAM) | ||
| JP2009541206A5 (OSRAM) | ||
| JP2009530302A5 (OSRAM) | ||
| JP5240941B2 (ja) | Ｐ２ｘ７調節因子としてのビシクロへテロアリール化合物およびその使用 | |
| CA2680275C (en) | Bicycloheteroaryl compounds as p2x7 modulators and uses thereof | |
| JP5306987B2 (ja) | Ｐ２ｘ７調節因子としてのビシクロへテロアリール化合物およびその使用 | |
| JP2010524930A5 (OSRAM) | ||
| JP2008534511A (ja) | Ｐ２ｘ７調節因子としてのビシクロヘテロアリール化合物およびその使用 | |
| US20100184802A1 (en) | Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof | |
| WO2007109154A2 (en) | Bicycloheteroaryl compounds as p2x7 modulators and uses thereof | |
| JP2008537741A5 (OSRAM) | ||
| WO2007109182A2 (en) | Bicycloheteroaryl compounds as p2x7 modulators and uses thereof | |
| JP2010526069A5 (OSRAM) | ||
| PT2007752E (pt) | Benzoimidazol-2-il pirimidinas e pirazinas como moduladores do receptor de histamina h4 | |
| JP2007518790A (ja) | 疾患の治療のためのスルフォンアミド誘導体 | |
| JP2019532054A5 (OSRAM) | ||
| JP2018529643A (ja) | ユビキチン化−プロテアソーム系に関連する化合物および薬学的組成物 | |
| RU2018144774A (ru) | Антагонист trpv4 | |
| WO2005115147A2 (en) | Hiv reverse transcriptase inhibitors | |
| JP2009541205A5 (OSRAM) | ||
| JP2009185060A (ja) | カンデサルタンシレキセチル多形体 | |
| HK1136967B (en) | Bicycloheteroaryl compounds as p2x7 modulators and uses thereof | |
| JP2009541205A (ja) | Ｐ２ｘ７調節因子としてのビシクロへテロアリール化合物およびその使用 |